Trial of CHOP versus CIOP in Good Risk Stage II-IV Patients with Histologically Aggressive Non-Hodgkin's Lymphoma
- Conditions
- ymphoma (non-Hodgkin's)CancerLymphoma (non-Hodgkin's)
- Registration Number
- ISRCTN26863825
- Lead Sponsor
- British National Lymphoma Investigation (BNLI) (UK)
- Brief Summary
2005 results in: https://www.ncbi.nlm.nih.gov/pubmed/16098067 (added 31/10/2019)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 211
1. Age 16-59 years
2. No medical conditions, other than lymphoma, prohibiting intensive therapy and no systemic treatment for cancer in previous 5 years
3. One of the following histological types:
3.1 Follicular large cell
3.2 Diffuse mixed cell
3.3 Diffuse large cell
3.4 Diffuse immunoblastic lymphomas
4. Full clinical staging to include Computed Tomography (CT) scanning of abdomen and bone marrow trephine biopsy
5. Good prognostic features defined as the presence of less than two of:
5.1 Stage III/IV
5.2 Lactic dehydrogenase (LDH) >normal
5.3 Eastern Cooperative Oncology Group (ECOG) or World Health Organisation (WHO) performance status 2-4
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration